Rapid molecular testing for antimicrobial resistance (AR) provides an indication of resistance faster than phenotypic antimicrobial susceptibility testing. We summarize the adoption of molecular testing for AR among US acute care hospitals and discuss the potential impact on National Healthcare Safety Network’s surveillance for AR.